Russ Altman is the Kenneth Fong Professor of Bioengineering, Genetics, Medicine, Biomedical Data Science and (by courtesy) Computer Science at Stanford University. His primary research interests are in the application of computing to problems relevant to medicine. Kim Branson is a senior vice president and Global Head of Artificial Intelligence and Machine Learning at GSK, where he leads the GSK.ai team, a group of nearly 100 machine learning researchers and engineers who are pioneering the application of AI to drug discovery and development. In this conversation with Stanford adjunct lecturer and STVP Director of Principled Entrepreneurship Jack Fuchs, Altman and Branson discuss how ethics and principles can shape innovation at the intersection of AI and drug development.
Related

John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.
Video
53 minutes
John Felts,
Cruz Foam
Engineering Green Materials [Entire Talk]
To scale a technology, engineers need to think beyond the technology itself.

Kristen Fortney,
BioAge Labs
Derisking Biotech [Entire Talk]
Biotech offers huge rewards for founders who approach risk strategically.
Video
53 minutes
Kristen Fortney,
BioAge Labs
Derisking Biotech [Entire Talk]
Biotech offers huge rewards for founders who approach risk strategically.

Alfred Lin,
Sequoia Capital
Developing a Founder’s Mindset [Entire Talk]
Strategic founders pursue calculated risks and are willing to evolve.
Video
54 minutes
Alfred Lin,
Sequoia Capital
Developing a Founder’s Mindset [Entire Talk]
Strategic founders pursue calculated risks and are willing to evolve.